What’s the latest about Alzheimer’s’s dementia?
Answers
Existing Alzheimer’s medicines only help with memory loss and thinking and reasoning issues for a short time.
These Alzheimer’s treatments stimulate the activity of neurochemicals to improve cell communication. These medicines, however, do not prevent the underlying decrease and death of brain cells. Alzheimer’s disease worsens as more cells die.
There is cautious optimism among Alzheimer’s experts that there will be new therapies that can either halt or greatly slow the progression of Alzheimer’s. Increasing knowledge of how the illness affects and damages the brain has led to possible Alzheimer’s treatments that can stop or reverse its advance.
As with many cancer and HIV/AIDS medicines, future Alzheimer’s treatments may include a combination of medications.
The following are some of the therapy alternatives that are currently under study:
Targeting the plaques
Beta-amyloid clumps are being targeted by several novel Alzheimer’s medicines in development (plaques). Plaques are a common symptom of Alzheimer’s disease.
Among the anti-beta-amyloid strategies are:
Get the immune system to do the job.
Antibodies known as monoclonal antibodies may prevent or remove beta-amyloid plaques from forming, and they may also aid in the removal of beta-amyloid plaques that have already developed.
Monoclonal antibodies are antibodies that your body naturally creates as part of your immune system’s reaction to foreign invaders or vaccines.
The Food and Drug Administration (FDA) authorized aducanumab to treat specific types of Alzheimer’s disease in June 2021.
Amyloid plaques are a primary cause of Alzheimer’s disease, and this is the first medicine that has been approved in the US to target and removes them. However, FDA approval was contingent on more research demonstrating the drug’s effectiveness. In addition, experts need to determine which patients could benefit from the medicine.
With promising results in amyloid removal, the monoclonal antibody Lecanemab is now proceeding into phase 3 clinical trials.
Phase 2 studies of Donanemb, another monoclonal antibody that demonstrated promising results, have progressed to Phase 3 testing.
There is no evidence that the monoclonal antibody solanezumab helps those with mild or severe Alzheimer’s disease. Solanezumab may be more effective if taken early in the condition. In recent studies, the medicine appeared to be safe, and solanezumab is still under test in the preclinical stage of the disease.
Keep the destruction at bay.
Saracatinib, a drug created as a potential cancer treatment, is now being tested for Alzheimer’s disease.
The medicine reversed partial memory loss in rats by turning off a protein that allowed synapses to function again. Saracatinib is now under the testing phase as a potential Alzheimer’s disease treatment.
Halt the production.
These treatments can lower the quantity of beta-amyloid that forms in the brain. According to research, beta-amyloid is created in two steps by distinct enzymes from a “parent protein,” according to the study.
These enzymes are the main focus of the several experimental medicines currently in development.
In the scientific community, they know them as inhibitors of beta and gamma-secretase. Beta-secretase inhibitors didn’t slow down cognitive decline and had a lot of side effects in people with mild or moderate Alzheimer’s, which has made people less excited about this type of drug.
Alzheimer’s is a progressive neurologic disorder that makes the brain shrink and brain cells die. It’s the most common cause of dementia (a continuous decline in thinking and social skills). The latest things that are done about Alzheimer’s and dementia are as follows:
1. Scientists have identified a rear population of potentially toxic senescent in the human brain that can target a new Alzheimer’s disease treatment.
2. Reading frailty in order adults could be an effective strategy to prevent dementia.
3. Food and Drug Administration (FDA) agreed on aducanumab to cure some cases of Alzheimer’s disease.
4. Aduhelm is the first medication on the market that can remove amyloid, the sticky substance made in the brains of Alzheimer’s patients.
As someone whose dad has Alzheimer’s, I know that experts are trying to develop Alzheimer’s treatment to stop or delay the symptoms of this disease. A new drug called aducanumab can treat the underlying causes of the disease. It targets and removes the amyloid plaques in the brain.
There are so many fresh hypotheses popping up everywhere these days: Diet; Viruses; Lack of activity; Trauma. I have to agree that trauma may cause neurological damage, and I’ve noticed several mental health issues that appear to run in families. It has a vital hereditary component, in my opinion. Others believe it runs in families but blames it on their foods or other lifestyle habits.
Although I’ve been warned not to put too much faith in NAD+, NMN, and other basic cures, I believe they’re worth a go. Many new studies are being conducted, and I guess effective remedies will emerge in the US in 10–15 years.
Remember that other countries have their drug testing and systems in place, so it’s a good idea to investigate there as well. However, Alzheimer’s disease causes observable structural changes in the brain. If it’s detected, seek treatment as soon as possible!
That’s all we can do for the time being. For those of us who are still here, remember that antioxidants are beneficial for all of our cells, and DHA is a significant component of the brain, so take your DHA (fish oil or borage oil) supplement.
